On the contrary, epithelial-mesenchymal transition (EMT), as well as other immune and oncogenic signaling pathways, such as tumor necrosis factor alpha (TNF-α), complement cascades, and IL6 JAK-STAT3 signaling, were enriched in the CIS group (Fig. 4b, c). The gene discussed is STAT3; the disease is in situ carcinoma.